Rayburn W, Donn S, Compton A, Piehl E
Department of Obstetrics and Gynecology, University of Nebraska Medical Center, Omaha 68105.
J Perinatol. 1989 Sep;9(3):268-70.
This investigation was undertaken to compare maternal and neonatal cord serum levels of phenobarbital given orally to mothers anticipated to deliver very low birthweight infants at risk for neonatal intraventricular hemorrhage (IVH). Fifty women anticipated to deliver between 26 and 34 weeks' gestation agreed to receive a daily oral dose of 90 mg of phenobarbital. The umbilical cord to maternal phenobarbital concentration ratio at birth was 1.05 and remained constant after the first day of maternal therapy. Cord phenobarbital concentrations increased rapidly during the first 3 days until reaching a steady state by the end of the first week of therapy. In contrast to recent promising reports using large doses of phenobarbital given parenterally shortly before delivery, lower doses of oral phenobarbital did not reach cord levels reported to be protective against IVH or therapeutic as an anticonvulsant.
本研究旨在比较口服苯巴比妥的母亲及其新生儿脐带血清中苯巴比妥的水平,这些母亲预计会分娩极低出生体重儿,且其新生儿有发生脑室内出血(IVH)的风险。五十名预计在妊娠26至34周分娩的妇女同意每日口服90毫克苯巴比妥。出生时脐带与母体苯巴比妥浓度之比为1.05,且在母亲治疗第一天后保持恒定。脐带苯巴比妥浓度在治疗的前3天迅速升高,直到治疗第一周结束时达到稳定状态。与近期关于在分娩前不久胃肠外给予大剂量苯巴比妥的有前景的报告相反,较低剂量的口服苯巴比妥未达到据报道对IVH有保护作用或作为抗惊厥药有治疗作用的脐带水平。